Back to Journals » OncoTargets and Therapy » Volume 7

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

Authors Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas T

Received 9 December 2013

Accepted for publication 14 February 2014

Published 8 May 2014 Volume 2014:7 Pages 697—702

DOI https://doi.org/10.2147/OTT.S58902

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5


Chiara Catania,1 Fabio Conforti,1 Gianluca Spitaleri,1 Massimo Barberis,2 Lorenzo Preda,3 Cristina Noberasco,1 Chiara Lazzari,1 Francesca Toffalorio,1 Filippo de Marinis,1 Michela Manzotti,2 Tommaso Martino De Pas1

1Division of Thoracic Oncology, 2Division of Pathology, 3Division of Radiology, European Institute of Oncology, Milan, Italy

Abstract: We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of gastrointestinal stromal tumor and also in several cases of acral and mucosal melanomas. Some of the patients with gastrointestinal stromal tumor or melanoma harboring this rare mutation have had a tumor response when treated with imatinib. In contrast, in our case, the mutation was associated with primary resistance to full doses of imatinib but, at the same time, it was not a cause of resistance to sorafenib.

Keywords: sorafenib, imatinib, thymic carcinoma

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]